NCT04788017View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 24, 2021

Primary Completion Date

June 14, 2021

Study Completion Date

July 22, 2021

Conditions
Healthy Subjects
Interventions
DRUG

Ziresovir

"Planned treatments are:~* Cohort 1: 300 mg of ziresovir~* Cohort 2: up to 600 mg of ziresovir~* Cohort 3: up to 900 mg of ziresovir"

OTHER

Placebo

"Planned treatments are:~* Cohort 1: 300 mg of placebo~* Cohort 2: up to 600 mg of placebo~* Cohort 3: up to 900 mg of placebo"

Trial Locations (1)

07094

Frontage, Secaucus

All Listed Sponsors
lead

Shanghai Ark Biopharmaceutical Co., Ltd.

INDUSTRY

NCT04788017 - A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects | Biotech Hunter | Biotech Hunter